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Abstract 
Background: Iran has a large group of patients with severe congenital factor 
XIII deficiency (FXIIID) and Trp187Arg mutation that is most disease 
causing mutations of FXIII in the world is only observed in the southeast of 
Iran in 352 patients with FXIIID. 743 patients with FXIIID was observed in 
17 provinces of Iran, but Tehran city with more than 12 million population 
has no any registered patient with FXIIID. Here we described the first case 
with severe congenital FXIIID in Tehran Province with underline FXIII 
mutation. 
MaterialsandMethods:A neonate with prolonged umbilical cord bleeding 
was referred to hemophilia center. The patient was screened by routine 
coagulation tests and by clot solubility test. After observation of normal 
routine tests and abnormal clot solubility patient was undergoing a full 
sequencing of FXIII-A gene. For confirmation of detected mutation in FXIII-
A gene, exon 4 was amplified by PCR and cleaved by Eco130I restriction 
enzyme. 
Results:We found the first case with severe congenital FXIIID in Tehran 
Province with Trp187Arg mutation in exon 4 of FXIII-A gene. Patient’s 
parents were heterozygote for this mutation. 
Conclusion:Trp187Arg mutation of FXIII-A is the most common mutation in 
Iranian patients with FXIIID and is not restricted to southeast of Iran. 
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Introduction 
Coagulation factor XIII (FXIII) is a tetrameric 
transglutaminase, consist of two subunits A (FXIII-A) 
with catalytic function and two B subunits (FXIII-B) 
as a carrier (A2B2) that held together by non-covalent 
bond. FXIII-A is synthesized by cells of bone marrow 
origin, whereas FXIII-B is produced by hepatocytes. 
In the final stage of blood coagulation, FXIII 
stabilizes fibrin clots and protects it from proteolytic 
degradation by the fibrinolytic system by formation of 
covalent crosslinks between γ-glutamyl and ε-lysyl 
residues of fibrin monomers after activation by 
thrombin (1-3).  
FXIII deficiency (FXIIID) is extremely rare. 
Bleeding disorder occurs approximately 1 in 5 million 
prevalence in the general population (1, 4). Most 
affected patients have deficiency of A subunit. 
c.559 T>C as The Most Common Mutation of Factor XIII Deficiency…Dorgalalehet al. 
Vol1, No 4, Fall2016 
155 
Clinical manifestations of FXIII deficiency including 
umbilical cord bleeding, delayed wound healing, 
subcutaneous and soft tissue bleeding, recurrent 
abortion and pregnancy loss and intracranial bleeding 
as the main cause of death in affected patients (4-7). 
Most of bleeding episodes are seen in patients with 
severe deficiency (activity of FXIII is less than 1%). 
Clot solubility test in urea, acetic acid or 
monochloroacetic (MCA) acid has done for detection 
of FXIIID, but this test detects only severe form of 
FXIII deficiency and mild and moderate forms of 
FXIIID are diagnosed by quantitative assay such as 
amine incorporation and ammonia release assays (2, 
8-10). In regions with a high rate of consanguineous 
marriage number of affected patients with rare 
bleeding disorders (RBDs) such as FXIIID are 
significantly higher (11, 12). The prevalence of 
FXIIID in Iran is very higher than the overall 
frequency in the rest of the world and the number of 
FXIIID in Iran was 473 patients in 2014. Although 
many studied have been performed in this country, 
but up to now any study about FXIIID has not been 
reported in Tehran Province (1). In This study, we 
assessed a new case of FXIIID in Tehran Province. 
Methods 
This study was performed in Tehran Province, 
central Iran. The study was approved by Iran 
University of Medical Sciences and a written consent 
was obtained from patients’ parents. A neonate with 
unusual prolonged bleeding was referred to a 
physician. The neonate was referred to hemophilia 
laboratory. Initially a structural questionnaire was 
filled by interview of the patient’s parents by a trained 
staff to obtain demographic data and any family 
history of FXIIID. 
Then the patient was screened by routine 
coagulation tests, including Activated Partial 
Thromboplastin Time (APTT), Prothrombin Time 
(PT) (DiagnosticaStago -France kits and semi-
automatic coagulation analyzer, STAGO, STart®), 
Bleeding Time (BT) (Ivy method) and platelet count 
(Sysmex kx_21 hematology analyzer). Since the 
factor XIII activity assay is not performed in Iran as a 
screening test for diagnosis of FXIIID, the patient was 
assessed by clot solubility test in an MCA acid 
environment (13). With observation of a normal 
routine coagulation tests and an abnormal clot 
solubility test patient was undergoing further 
investigations for the detection of underline FXIII-A 
gene mutation.  
At baseline blood specimens with EDTA 
anticoagulants were drawn from all selected patients 
in order to isolate genomic DNA. DNA was obtained 
from the blood specimen after lysis with sodium 
dodecyl sulfate and proteinase K treatment of buffy 
coat. DNA was purified using phenol–chloroform and 
ethanol precipitation. The quality and quantity of 
DNA obtained were determined by spectrophotometer 
and also by means of agarosegel electrophoresis. 
Following DNA extraction, the coding region, 
intron/exon boundaries and 5’ and 3’ untranslated 
regions (UTR) of the FXIII gene were amplified by 
polymerase chain reaction (PCR). Amplified 
fragments were directly sequenced using an 
automated sequencer (Applied Biosystems, Foster 
City, CA). For confirmation of identified mutations, 
sequencing were repeated and in cases with a 
digestion site for the restriction enzyme (RE), 
amplified fragment was digested by appropriate RE 
under standard condition. After mutation detection, 
the patients’ parents DNA was amplified with PCR 
and was digested by Eco130I (Fermentas Life 
Sciences, York, UK) according to the manufacturer’s 
instruction. PCR and digestion conditions were 
described previously (14). 
Results 
The patient was a male neonate with prolonged 
cord bleeding. All routine coagulation tests were 
normal in this patient and clot solubility test was 
abnormal. Neonate did not receive any replacement 
therapy. Molecular analysis of FXIII-A gene revealed 
C.559T>C neucleotid exchange in exon 4 which lead 
to tryptophan to arginine substitution in FXIII A 
subunit (Trp187Arg).  
This amino acid exchange affects FXIII-A 
chain structure and probable instability of this subunit 
and in the homozygous condition cause severe factor 
XIII deficiency. After detection of this mutation, 
tepatients’ parent exon 4 product (a 513bp fragment) 
was cleaved by Eco130I and in both 4 fragments, 
including– 460, 392, 68 and 53 bp fragments was 
observed after digestion that was consistent with the 
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heterozygous state for Trp187Arg mutation. 
Discussion 
FXIIID is an extremely rare hemorrhagic 
disorder with an estimated prevalence of 1 per 2 
million in the general population. Iran as a Mideast 
country has the highest population of patients with 
FXIIID worldwide. FXIIID has an approximately 12 
fold higher prevalence in Iran in comparison with an 
overall incidence of FXIIID in the world (1-4, 12). 
Among different provinces of Iran, Sistan and 
Baluchestan, southeast of Iran has the highest rate of 
FXIIID. This high prevalence of FXIIID in Iran is a 
result of the high rate of contagiousness marriage in 
this country (1, 12-14). Our previous study on FXIIID 
in Iran revealed 473 cases with severe congenital 
FXIIID in this country. Most of these cases (352 
cases) were residents of Sistan and Baluchestan 
Province, southeast of Iran and all of patients in this 
area in except of 2 patients had Trp187Arg mutation 
in FXIII-A gene (1, 2,14-16). But this mutation was 
not observed in any other part of the country. 
Moreover, in our previous study, we did not find any 
patient with FXIIID in Tehran Province. In our study, 
we found patients with FXIIID in 17 provinces of 
Iran, but in Tehran Province as capital of Iran with the 
highest population among Iran provinces, we did not 
find any case with FXIIID and this case is the first 
one in this province (1-3). In this neonate we found 
Trp187Arg mutation in exon 4 that was same with 
only observed mutation in southeast of Iran. This 
finding was confirmed that Trp187Arg mutation is the 
most common in Iranian patients and is not restricted 
to southeast of Iran. Previously, we used this mutation 
for carrier detection and prenatal diagnosis (PND) 
only in southeast of Iran (1, 8-12). With this new 
finding, we can offer this mutation as the first step in 
 
Fig. 1.Observed mutation in position of 559 with substitution of C instead of T 
 
Fig. 2.PCR-RFLP for c.559T>C mutation confirmed the results of DNA sequencing 
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carrier detection and confirmation of FXIIID in 
suspected patient to FXIIID in all over the Iran (1-5). 
Since, in Iran, FXIII assay is not used for FXIII 
detection, a simple PCR-RFPL can used as a fast and 
reliable method for carrier detection and confirmation 
of FXIIID in suspected patients. 
Conclusion 
c.559T>C as the most common mutation of 
FXIII-A gene in Iranian patients is not restricted to 
southeast of Iran and can be used as the first screening 
mutation for diagnosis of disorder in Iran. 
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